drugset / Trial / NCT03061708
Trial of Single Agent AZD2014 in RICTOR Amplified GC Patients as Second-line Therapy
NaSingle-groupOpen-labelTreatment
Summary
Phase II trial of AZD2014 in RICTOR amplified or overexpressed GC patients as second-line chemotherapy AZD2014 50mg BD continuous schedule of a 28 day cycle
Timeline
- Start
- 2017-02-01
- Primary completion
- 2018-11-16
- Completion
- 2018-11-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vistusertib | Small molecule | 50 mg | — |